Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
What is fatty liver disease?
Fatty liver disease is a common medical condition that occurs when excess fat accumulates in and around the liver. It is estimated that 25% of Canadians may have fatty liver disease, and most do not even know it. Fatty liver disease is often found in people who have a high BMI, and those who have diabetes.
Stages and Causes of Fatty Liver Disease
MASLD HAS NOW REPLACED NAFLD and NASH
New Nomenclature for NAFLD and NASH
At EASL 2023 in Vienna, Austria, the new nomenclature was officially launched.‘ A multi-society Delphi consensus statement on new fatty liver disease nomenclature’. Published in Hepatology, Journal of Hepatology and Annals of Hepatology.
Video
NAFLD, NASH and Atrial Fibrillation
Can atrial fibrillation be detected with transient elastography? Find out more from Laurens van Kleef as he discusses his recently published paper in Hepatology, with Michael Betel from the Fatty Liver Alliance.
NAFLD and NASH in the Elderly
Should patients over 65 be assessed for fatty liver disease? Does recent data demonstrate any benefit? Watch as Laurens van Kleef discusses this important issue.
Fatty Liver Disease Videos
The Silent Epidemic of Non-Alcoholic Fatty Liver Disease
Dr. Giada Sebastiani, Hepatologist, presents an excellent overview of nonalcoholic fatty liver disease (NAFLD).
Do we really know the incidence of Fatty Liver Disease?
Dr. Naim Alkouri, is a Hepatologist, and the co-author of this important and recent Texas study with 664 inclusion qualifying participants (a cohort of asymptomatic middle-aged US adults), highlights a higher prevalence of NAFLD and NASH than previously thought. Findings published in the Journal of Hepatology were: "Based on liver histology data, NASH was diagnosed in 14% of the entire cohort and 37% of those with NAFLD." "NASH was more common in Hispanics and those with obesity or type 2 diabetes."
"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort".
Authors: Stephen A. Harrison, Samer Gawrieh, Katharine Roberts, Céline Fournier, Angelo H. Paredes and Naim Alkhouri.
Mortality Impact of NAFLD
This very informative chat between Dr. Tracey Simon, Dr. Naim Alkhouri and Dr. Mark Swain could possibly change the way a NAFLD patient is treated. A landmark paper, published in GUT in July 2021 which included over 10k biopsy confirmed patients had incredible insights about the very serious outcomes of NAFLD. As a co-author, Dr. Simon summarizes the findings and it is followed by a great discussion. "Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort".
The Myths About Non-Alcoholic Fatty Liver Disease - Part 1
Dr. Nadege Gunn is a Gastroenterologist and Hepatologist and the Medical Director and President of Impact Research, in Waco Texas. She focuses mainly on finding therapies for liver related illnesses, with a special interest in NAFLD. Her work concentrates on linking cutting edge clinical trials in non-alcoholic fatty liver disease and gastrointestinal illnesses to the populations who need them desperately. She has a broad clinical research and community practice background.
The Myths About Non-Alcoholic Fatty Liver Disease - Part 2 - Is Weight Loss Enough?
Dr. Nadege Gunn is a Gastroenterologist and Hepatologist and the Medical Director and President of Impact Research, in Waco Texas. She focuses mainly on finding therapies for liver related illnesses, with a special interest in NAFLD. Her work concentrates on linking cutting edge clinical trials in non-alcoholic fatty liver disease and gastrointestinal illnesses to the populations who need them desperately. She has a broad clinical research and community practice background.
What is the incidence of Fatty Liver Disease?
Dr. Manal Abdelmalek, Hepatologist and Professor of Medicine at Duke University School of Medicine, discusses the important issue about incidence of Fatty Liver Disease. Are NAFLD and NASH more common than is currently believed by many?
Post AASLD 2021 Abstract Review
The leadership team of CanNASH, Dr. Mark Swain, Dr. Giada Sebastiani, Dr. Keyur Patel and Dr. Alnoor Ramji share and discuss with Michael Betel from the Fatty Liver Alliance, the AASLD - TMLdX abstracts they found most valuable in the world of NAFLD and NASH.
Mortality in Pediatric and Young Adults with NAFLD
"We know that there is a growing global epidemic of obesity and non-alcoholic fatty liver disease (NAFLD) among children and young adults. But there is not a lot of longitudinal data from large populations to quantify what the long-term prognosis is, what the long-term outcomes are for those children and young adults who are affected by NAFLD. What are the complications of NAFLD and the risks of overall mortality?
Today we have Dr. Tracey Simon, author of this important paper, with Dr. Mark Swain, Dr. Naim Alkhouri, and Michael Betel discussing the implications of this data for our children and young adults.
Fatty Liver Disease and Metabolic Syndrome
Dr. Manal Abdelmalek, Hepatologist and Professor of Medicine at Duke University School of Medicine, shares her informative experiences about nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and the association with obesity, diabetes and high cholesterol.
Nonalcoholic Fatty Liver Disease Why All The Fuss?
Dr. Supriya Joshi, Gastroenterologist and Hepatologist in Mississauga, Ontario, Canada shares a ton of very relevant and current information and studies about this very important liver disease.
Burden of NAFLD & NASH 2019-2030
NAFLD & NASH prevalence is projected to double in the next 10 years. There are actions we can take to address this...habits we can change now. Dr. Mark Swain , Gastroenterologist and Hepatologist discusses with NASHnet.ca. July 2020
Full published paper: Burden of nonalcoholic fatty liver disease in Canada, 2019–2030: a modelling study: http://cmajopen.ca/content/8/2/E429.full.pdf
The Impact of Covid-19 on Fatty Liver Disease and NASH
Dr. Manal Abdelmalek, Hepatologist and Professor of Medicine at Duke University School of Medicine, shares her clinical experience of how the Covid-19 pandemic has impacted her patients.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.